Form 4 for AIDX 20/20 Biolabs, Inc.

Accepted 2026-02-23 00:00:00 ET · period of report 2026-02-19 · accession 0001213900-26-019456 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DM	2026-02-23	2026-02-19	AIDX	Rollins John Woodson	Dir	C - Cnv Deriv	$0.00	+19.2K	30.3K	+172%	$0
DM	2026-02-23	2026-02-19	AIDX	Rollins John Woodson	Dir	C - Cnv Deriv	—	-19.2K	0	-100%	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-02-19	C	A	13,029	$0.00	24,140	D	—	—
2	Common	Common Stock	2026-02-19	C	A	6,135	$0.00	30,275	D	—	—
3	Derivative	Series A Preferred Stock	2026-02-19	C	D	13,029	—	0	D	— · — to —	13,029 Common Stock	(F1) On February 19, 2026, all shares of series A preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A preferred stock had no expiration date.
4	Derivative	Series A-2 Preferred Stock	2026-02-19	C	D	6,135	—	0	D	— · — to —	6,135 Common Stock	(F2) On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date.